Research ArticleCancer

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma

See allHide authors and affiliations

Science Translational Medicine  13 Mar 2019:
Vol. 11, Issue 483, eaau9732
DOI: 10.1126/scitranslmed.aau9732

Article Information

vol. 11 no. 483

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication August 3, 2018
  • Accepted for publication January 8, 2019
  • .

Author Information

  1. Renata Sano1,
  2. Kateryna Krytska1,
  3. Colleen E. Larmour1,
  4. Pichai Raman2,
  5. Daniel Martinez3,
  6. Gwenda F. Ligon4,
  7. Jay S. Lillquist4,
  8. Ulisse Cucchi5,
  9. Paolo Orsini5,
  10. Simona Rizzi5,
  11. Bruce R. Pawel3,
  12. Diego Alvarado4 and
  13. Yael P. Mossé1,6,*
  1. 1Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  2. 2Division of Oncology and Center for Biomedical Informatics (CBMi), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  3. 3Department of Pathology, Children’s Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
  4. 4Celldex Therapeutics Inc., New Haven, CT 06511, USA.
  5. 5Nerviano Medical Sciences S.r.l., Nerviano (MI) 20014, Italy.
  6. 6Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  1. *Corresponding author. Email: mosse{at}chop.edu

Altmetric

Article usage

Article usage: March 2019 to August 2019

AbstractFullPdf
Mar 20195125925510
Apr 20198819993
May 20192026743
Jun 20192254249
Jul 20191003944
Aug 2019622016